Enterprise Value
1.269M
Cash
144M
Avg Qtr Burn
-31.54M
Short % of Float
3.87%
Insider Ownership
1.13%
Institutional Own.
55.21%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tamibarotene (SY-1425) (RARα agonist) Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Tamibarotene (SY-1425) (RARα agonist) in combination with venetoclax and azacitidin Details Acute myeloid leukemia, Cancer Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Phase 2 Update | ||
SM-88 Details Sarcoma, Bone cancer, Breast cancer | Failed Discontinued | |
SM-88 Details Pancreatic cancer | Failed Discontinued | |
SM-88 Details Prostate cancer, Prostate disease | Failed Discontinued | |
SM-88 Details Sarcoma, Bone cancer | Failed Discontinued | |
Failed Discontinued | ||
TYME-19 Details COVID-19 | Failed Discontinued |